IMUGENE LIMITED (IMU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMU - IMUGENE LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.037

21 Nov
2024

-0.003

OPEN

$0.04

-7.50%

HIGH

$0.04

58,353,906

LOW

$0.04

TARGET
$0.10 170.3% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMU: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 2.1 - 1.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-2.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx1.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-97.3 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-97.23 %
Return on Invested Capital xxxxxxxxxxxxxxx-96.92 %
Return on Assets xxxxxxxxxxxxxxx-85.91 %
Return on Equity xxxxxxxxxxxxxxx-97.23 %
Return on Total Capital xxxxxxxxxxxxxxx-90.93 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-104.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx93 M
Price To Book Value xxxxxxxxxxxxxxx3.53

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx9.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx6 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx135 M
Research & Development xxxxxxxxxxxxxxx87 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

12/09/2024

1

Speculative Buy

$0.10

170.27%

Bell Potter considers the interim trial data post 12-month ownership of Azer-cel as positive and results are "encouraging" in the most aggressive type of Non-Hodgkin Lymphoma, where there is no established standard of care for sufferers.

The analyst highlights the initial safety data were positive with the trial patients reporting low levels of cytokine release syndrome which is reported as typical of CAR-T therapy. The effects were noted as "transitory".

An additional 1-16 patients are expected to be enrolled in cohort B with a possible interim update to completion of the trial in 2025.

Speculative Buy rating remains. Target price slips to 10c from 15c.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.30 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

IMU STOCK CHART

FNArena News on IMU

1
Rudi’s View: Mate, Where Have The Profits Gone?

Nov 06 2024 - Rudi's View
2
May In Review: Inflation Spoils The ASX Party

Jun 05 2024 - Australia
3
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
4
The Short Report – 07 Dec 2023

Dec 07 2023 - Weekly Reports
5
The Short Report – 16 Nov 2023

Nov 16 2023 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps